Villarrubia V G, Herrerías J M, Alvarez-Mon M, Chirigos M A
Servicio de Aparato Digestivo, Hospital Clínico Universitario Virgen de la Macarena, Sevilla.
Rev Esp Enferm Dig. 1998 Jul;90(7):514-22.
With the immunologic rationale exposed in the first part of this paper, the authors analyze a new experimental treatment which includes the combination of an antiviral (ribavirin) and an immunomodulator (AM3) in a model of hepatotoxic viral-infection in mice. Rationale for this associated treatment is based on the ability of AM3 to restore the natural immunity through the induction of IL-12 and IFN-gamma. Furthermore, the treatment with AM3 decreases factor C3 of the complement system which appears to be implied in IL-12 downregulation. Experimental and clinical results showed herein suggest a new approach to the treatment of viral hepatitis which combines the use of antivirals in combination with immunomodulators able to restore the "immunologic chaos" induced by some viruses.
基于本文第一部分阐述的免疫学原理，作者分析了一种新的实验性治疗方法，该方法在小鼠肝毒性病毒感染模型中采用了一种抗病毒药物（利巴韦林）和一种免疫调节剂（AM3）联合使用。这种联合治疗的原理基于AM3通过诱导白细胞介素-12（IL-12）和γ-干扰素（IFN-γ）来恢复天然免疫的能力。此外，AM3治疗可降低补体系统的C3因子，而C3因子似乎与IL-12的下调有关。本文展示的实验和临床结果提示了一种治疗病毒性肝炎的新方法，即联合使用抗病毒药物和能够恢复某些病毒所诱导的“免疫紊乱”的免疫调节剂。
